Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | PEPD | P12955 | 2/20 | 0.47 |
| ▸ | XPNPEP1 | Q9NQW7 | 1/20 | 0.44 |
| ▸ | ACE | P12821 | 3/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL683441 | 0.87 | LMNA (0.52) | POLBFKBP1AALDH1A1LMNARAB9A | |
| SCHEMBL7333530 | 0.85 | POLB (0.54) | POLBFKBP1AALDH1A1LMNARAB9A | |
| SCHEMBL4179454 | 0.85 | FKBP1A (0.55) | POLBFKBP1AALDH1A1LMNARAB9A | |
| SCHEMBL13662643 | 0.85 | FKBP1A (0.55) | POLBFKBP1AALDH1A1LMNARAB9A | |
| SCHEMBL7333522 | 0.85 | POLB (0.54) | POLBFKBP1AALDH1A1LMNARAB9A | |
| SCHEMBL683098 | 0.84 | FKBP1A (0.53) | FKBP1AALDH1A1LMNARAB9ASMN1; SMN2 | |
| SCHEMBL23135776 | 0.83 | ALDH1A1 (0.54) | POLBFKBP1AALDH1A1LMNARAB9A | |
| SCHEMBL2606998 | 0.83 | ALDH1A1 (0.54) | POLBFKBP1AALDH1A1LMNARAB9A | |
| SCHEMBL4437850 | 0.83 | POLB (0.52) | POLBFKBP1AALDH1A1LMNARAB9A | |
| SCHEMBL8248348 | 0.83 | POLB (0.52) | POLBFKBP1AALDH1A1LMNARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110269717-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | BRAINCELLS INC. (US) | 2011-11-03 | — | — | US | disclosed |
| US-20110046090-A1 | MODULATION OF NEUROGENESIS WITH GABA AGENTS AND GABA ANALOGS | BRAINCELLS INC. (US) | 2011-02-24 | — | — | US | disclosed |
| US-20110046090-A1 | MODULATION OF NEUROGENESIS WITH GABA AGENTS AND GABA ANALOGS | BRAINCELLS INC. (US) | 2011-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046090-A1 | MODULATION OF NEUROGENESIS WITH GABA AGENTS AND GABA ANALOGS | GAP43, GABRB1, GABRB3 | POLB 1250/4885FKBP1A 1039/4885ALDH1A1 1041/4885 |
| US-20110269717-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | NGF, DCX, BDNF | POLB 1723/4885FKBP1A 1111/4885ALDH1A1 1565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.